CD7 antibody targets the CD7 antigen, a 40 kDa cell surface glycoprotein belonging to the immunoglobulin superfamily. CD7 is primarily expressed on T cells, natural killer (NK) cells, and early thymocytes, playing roles in cell-cell interactions and signal transduction. It is implicated in T-cell activation, adhesion, and apoptosis regulation, though its exact physiological ligands and functions remain partially understood.
CD7 antibodies have become vital tools in research and clinical diagnostics. In hematopathology, they are used for immunophenotyping via flow cytometry to identify T-cell malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and certain lymphomas, where CD7 expression is often aberrant. Therapeutically, CD7-directed antibodies are being explored in novel treatments. Anti-CD7 antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapies target CD7-positive malignancies, showing promise in early trials. However, challenges persist due to CD7’s broad expression on normal T cells, risking immunosuppression. Strategies like CD7 gene editing in CAR-T cells aim to mitigate "self-targeting" issues.
Additionally, CD7 antibodies are studied in autoimmune and infectious diseases, given their role in modulating immune responses. Despite progress, further research is needed to fully elucidate CD7’s biological pathways and optimize therapeutic applications. Overall, CD7 antibodies represent a critical intersection of diagnostic utility and emerging immunotherapy innovation.